{"database":"iProX","file_versions":[],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["Xianzhong Cheng"],"species":["Homo Sapiens"],"full_dataset_link":["http://www.iprox.org/page/project.html?id=IPX0018238000"],"submitter_email":["cxxxxcyd@gmail.com"],"submitter_affiliation":["The Affiliated Cancer Hospital of Nanjing Medical University"],"sample_protocol":[""],"repository":["iProX"],"data_protocol":[""],"additional_accession":[]},"is_claimable":false,"name":"Tumor-Derived Extracellular Vesicle Proteomics Enables Precise Ovarian  Cancer Liquid Biopsy","description":"Ovarian cancer (OC) remains one of the most lethal gynecological malignancies, and effective non-invasive biomarkers for early diagnosis, postoperative monitoring, and prognosis assessment are still limited. Serum CA125, the current standard biomarker for OC, has limited diagnostic accuracy, particularly in early-stage disease. Cancer-derived extracellular vesicles (EVs) carry tumor-specific proteomic information and represent promising biomarkers; however, their sensitive and specific isolation from complex biological fluids remains challenging. In this project, we developed BP-EVlent, a novel approach that combines polyethylene glycol (PEG)-based precipitation with CA125 immunoaffinity capture to precisely isolate plasma CA125-positive EVs from patients with OC. The performance of BP-EVlent was evaluated using data-independent acquisition mass spectrometry (DIA-MS)-based proteomic analysis of plasma samples from healthy controls (HC), preoperative OC patients (OC-pre), and postoperative OC patients (OC-post","dates":{"publication":"Mon Jul 13 00:00:00 GMT+01:00 2026"},"accession":"PXD080966","cross_references":{"TAXONOMY":["9606"]}}